Related Experiment Video

Updated: May 10, 2026

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
07:46

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Published on: June 5, 2012

Utilization of Inhaled Antibiotics in Pediatric Non-Cystic Fibrosis Bronchiectasis: A Comprehensive Review

Maria Tsouprou1,2, Despoina Koumpagioti3, Evanthia Botsa2

  • 1Pediatric Allergy and Respiratory Unit, 3rd Department of Pediatrics, "Attikon" University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece.

Antibiotics (Basel, Switzerland)
|February 26, 2025
PubMed

Insights

Inhaled antibiotics may benefit children with non-cystic fibrosis bronchiectasis and frequent infections, potentially reducing exacerbations and bacterial load. However, evidence in this pediatric group is limited, requiring further research.

Area of Science:

  • Pediatric Pulmonology
  • Infectious Diseases
  • Respiratory Medicine

Background:

  • Pediatric non-cystic fibrosis bronchiectasis presents a growing concern with increasing detection rates.
  • Recurrent infections are a primary driver of lung function decline and increased morbidity/mortality in these children.
  • Early recognition and treatment are crucial as pediatric non-CF bronchiectasis can be reversible.

Purpose of the Study:

  • To review current data on inhaled antibiotic use in pediatric non-CF bronchiectasis.
  • To assess the safety and efficacy of inhaled antibiotics in this specific patient population.
  • To evaluate the potential benefits for managing recurrent infections and disease progression.

Main Methods:

  • Systematic review of existing literature on inhaled antibiotic therapy.
  • Analysis of safety and efficacy data, with a focus on pediatric studies.
  • Evaluation of impact on exacerbation rates and bacterial load, particularly Pseudomonas aeruginosa.

Main Results:

  • Inhaled antibiotics show potential as an adjuvant treatment for frequent exacerbations and Pseudomonas aeruginosa infections.
  • Observed benefits include reduced exacerbation rates and decreased bacterial load with minimal safety concerns.
  • The current evidence base specifically for children with non-CF bronchiectasis is notably limited.

Conclusions:

  • Inhaled antibiotics may be considered for a subgroup of pediatric non-CF bronchiectasis patients with frequent exacerbations and P. aeruginosa.
  • Further high-quality research is essential to establish the validity and optimal use of this treatment in children.
  • The low level of evidence necessitates caution and underscores the need for dedicated pediatric trials.

Keywords:
Pseudomonas aeruginosachildrencolistininhaled antibioticsnon-CF bronchiectasistobramycin

More Related Videos

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives10:26

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...